Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Similar documents
Comparative Billing Report

Chapter 17 Medical Policy

SLEEP STUDIES AND THERAPY MANAGEMENT

MODULE. POSITIVE AIRWAY PRESSURE (PAP) Titrations

Treatment of Obstructive Sleep Apnea (OSA)

Restoring a good night s sleep

Titration protocol reference guide

Polysomnography in Patients with Obstructive Sleep Apnea. OHTAC Recommendation. Polysomnography in Patients with Obstructive Sleep Apnea

Name of Policy: Management of Obstructive Sleep Apnea Syndrome

HEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE

Summary of AASM Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea - Updated July 2012

ROLE OF ORAL APPLIANCES TO TREAT OBSTRUCTIVE SLEEP APNEA

FREQUENTLY ASKED QUESTIONS

Helpful hints for filing

Changes in the Evaluation and Treatment of Sleep Apnea

Diagnosis and Treatment

Sleep Test Optimization Program Frequently Asked Questions Table of Contents

Dental Sleep Medicine

Understanding Sleep Apnea

DME PROVIDER Manual. Cigna Sleep Management Program General Information Module

2015 Physician Quality Reporting System Data Collection Form: Sleep Apnea (for patients aged 18 and older)

Obstructive Sleep Apnea Diagnosis and Treatment

Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome (Formerly part of Sleep Disorders Diagnosis/Treatment) (20118)

CPAP titration: PSG technologist or at Home

Billing for the treatment of OSA with oral orthotics:

Arlington Dental Associates Ira Stier DDS PC 876 Dutchess Tpk 2 Lafayette Ct. Poughkeepsie, NY Fishkill, NY

PAGE 1 OF 1 0 REFERENCE CURRENT EFFECT DATE 10/13 ORIGINAL ISSUE DATE 09/12 TITLE: SUBJECT: Patient Care

MEDICAL POLICY No R21 OBSTRUCTIVE SLEEP APNEA Including Uvulopalatopharyngoplasty (UPPP) and Laser - Assisted Uvulopalatoplasty (LAUP)

SERVICE: Obstructive Sleep Apnea: Diagnosis and Treatment.

Itamar Medical Coding and Reimbursement

DME: Definition... 2 Life Sustaining DME... 3 Oxygen Use Policy... 4 Non-Life Sustaining DME... 7

Compliance Issues in Home CPAP Therapy. Joseph Lewarski, BS, RRT, FAARC

Underwriting Sleep Apnea

Out of Center Sleep Testing and Auto-titrating CPAP: Gizmos and Gadgets. Kathleen Sarmiento, MD NAMDRC 2014

SERVICE: Obstructive Sleep Apnea: Diagnosis and Treatment.

Oxygen and Oxygen Equipment Coverage and Documentation Checklist

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

EXPECTATIONS OF PHYSICIANS INTENDING TO PRACTISE SLEEP MEDICINE CHANGING SCOPE OF PRACTICE PROCESS BACKGROUND

Comparing the Performance and Efficacy of the 3B/BMC RESmart. Auto-CPAP with the ResMed S9 AutoSet

Executive Summary. An American Academy of Sleep Medicine and American Academy of Dental Sleep Medicine Clinical Practice Guideline

About Sleep Apnea ABOUT SLEEP APNEA

Update on Home Sleep Studies Is there a Home for Portable Monitoring?

Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea

Occupational Therapy

Oxygen. 1554_0714_oxygen.pptx. Billing, Common Audit Errors and Tips to Avoid Them

DENTAL SLEEP PRACTICE

The New Blue Print What will the new sleep center look like?

Department of Pulmonology, Critical Care and Sleep Medicine, Bolan Medical College, Pakistan

Sleep Therapy I Ventilation I Patient Interface. Sleep Therapy. Sleep therapy solutions for every patient

Using home NIV for the management of hypercapnic COPD

Physical Therapy MM /15/2003

Cigna Medical Coverage Policy

Diseases and Health Conditions that can Lead to Daytime Sleepiness

Accuracy of Auto-Titrating CPAP to Estimate the Residual Apnea-Hypopnea Index in Patients

National Hospital for Neurology and Neurosurgery. Continuous positive airway pressure (CPAP) Sleep Respiratory Unit

New Mouthpiece Provides Relief for Truckers with Obstructive Sleep Apnea

A. Guide to Medicare Coverage

Every Download Tells a Story. Lizabeth Binns PA-C University of Michigan Sleep Center October 2, 2015

BCN e-referral Questionnaire Preview: Sleep study, outpatient facility or clinic-based setting

Acknowledgements. Dental Management of Obstructive Sleep Apnea in a Maxillofacial Prosthodontic Practice. Transfer of Information

Effective Treatment for Obstructive Sleep Apnoea

Treating Sleep Apnea A Review of the Research for Adults

Protocol. Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome

Sleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD

THERAPY SYSTEMS Therapy Systems

What is Obstructive Sleep Apnoea?

pii: jc

Overcoming CPAP Compliance Obstacles: Comfort is Key. Patient retention solutions and revenue generators for the Sleep Therapy Industry

Ministry of Health and Long Term Care Assistive Devices Program (ADP) Changes to How the ADP Funds Positive Airway Pressures Systems

Paul Wylie, MD 1, Sukhdev Grover, MD 2 1 Arkansas Center for Sleep Medicine, Little Rock AR; 2 Sleep Center of Greater Pittsburgh, Pittsburgh, PA

Obstructive Sleep Apnea (Not so) Sweet Dreams

Medicare C/D Medical Coverage Policy

Children Who Snore Do they have Sleep Apnea? Iman Sami, M.D. Division of Pulmonary and Sleep Medicine, Children s National

Does Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD

Table of Contents of AASM DME Accreditation Standards

Rapid Resolution of Intense Suicidal Ideation after Treatment of Severe. From the Department of Psychiatry and Psychology (L.E.K.

Fiberoptic bronchoscopy (FOB) is a procedure that pulmonologists

Standards for Accreditation of Non-Medicare Durable Medical Equipment (DME) Suppliers

SLEEP THERAPY GUIDE.

Each of us has our own

Growth Hormone Therapy

Respiratory Care. Provider Guide

Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015

CPAP Treats Muscle Cramps in Patients with Obstructive Sleep Apnea

Central, mixed and obstructive sleep apnea patient

Updates in Sleep Medicine for the Internist

KX Modifier Policy (Medicare)

Corporate Medical Policy Sleep Apnea: Diagnosis and Medical Management

Respiratory Medicine. Understanding Sleep Apnoea

DeVilbiss IntelliPAP AutoAdjust

Model of Care in a Comprehensive Sleep Program

1. CPAP: delivers continuous flow of air at a constant pressure.

Snoring and Obstructive Sleep Apnea (updated 09/06)

OBSTRUCTIVE SLEEP APNEA TREATMENT

Blue Cross Blue Shield of Michigan

OBSTRUCTIVE SLEEP APNEA TREATMENT

Medical Affairs Policy & Procedure

National Medical Policy

NUVIGIL (armodafinil) oral tablet

Transcription:

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Policy Number: Original Effective Date: MM.01.009 11/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/01/2015 Section: DME Place(s) of Service: Hospital; Sleep Lab; Home I. Description Obstructive sleep apnea syndrome (OSA) is characterized by repetitive episodes of upper airway obstruction due to the collapse and obstruction of the upper airway during sleep. The evaluation of OSA should be by clinical evaluation and overnight monitoring, either by attended polysomnography (PSG) or by portable unattended home monitoring under qualified supervision. This may be followed by a trial of auto-adjusting positive airway pressure (APAP) to evaluate efficacy and adjust pressure. Medical management of OSA includes weight loss, avoidance of stimulants, body position adjustment, oral appliances, and use of various types of positive airway pressure (PAP) devices. PAP devices include fixed continuous airway pressure (CPAP), CPAP devices that reduce pressure at the beginning of exhalation (CPAP with C-Flex ), auto-adjusting CPAP (APAP), bi-level positive airway pressure (bi-level PAP) and adaptive servo-ventilation (ASV). Bi-level PAP, ASV, and APAP devices are also referred to as respiratory assist devices (RAD). PAP therapy is the mainstay of therapy for adults with OSA. It involves the administration of air usually through the nose by an external device to maintain the patency of the upper airway. CPAP delivers a single, fixed pressure throughout the respiratory cycle. APAP adjusts the level of pressure as needed to maintain airway patency and then decreases the pressure if no abnormal respiratory events are detected within a set period of time. Bi-level PAP delivers a preset inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). ASV uses a servocontroller that automatically adjust pressure by breath-to-breath analysis to maintain a steady minute ventilation. Oral appliances can be broadly categorized as mandibular advancing/positioning devices or tongue-retaining devices. Oral appliances can either be "off the shelf" or custom made for the patient by a dental laboratory or similar provider. II. Criteria/Guidelines A. Continuous positive airway pressure (CPAP) and Auto-adjusting positive airway pressure (APAP) devices are covered (subject to Limitations and Administrative Guidelines) for an initial three

Positive Airway Pressure Devices for the Treatment of Obstructive Sleep Apnea 2 month trial period for the treatment of obstructive sleep apnea (OSA) when the following criteria are met: 1. The patient has a face-to-face clinical evaluation by the treating physician prior to the sleep test to assess for sleep related breathing disorder. The evaluation should include the following: a. Signs and symptoms of sleep disordered breathing, e.g., habitual and disruptive snoring, observed apneas, choking or gasping, excessive daytime sleepiness; b. Duration of symptoms; and c. Comorbid conditions, e.g., hypertension, ischemic heart disease, stroke. 2. Clinically significant OSA is documented by a polysomnogram performed by an appropriately accredited facility which demonstrates that the Apnea-Hypopnea Index (AHI) or Respiratory Disturbance Index (RDI) is greater than or equal to 5 events per hour. Note: See Appendix for definitions of apnea, hypopnea, apnea-hypopnea index (AHI), and Respiratory Disturbance Index (RDI). 3. CPAP will not be covered unless PAP titration has been initiated (and in most cases completed). a. If PAP cannot be titrated during supervised polysomnography performed in a sleep laboratory, then either a repeat PSG or auto-adjusting CPAP will be covered, subject to the criteria in the HMSA Polysomnography and Sleep Studies policy. b. Auto-adjusting positive airway pressure (APAP) is also covered for PAP titration in the home setting when the diagnostic study demonstrates OSA and there are no contraindications to home titration, subject to the criteria in the HMSA Polysomnography and Sleep Studies policy. B. Respiratory assist device (RAD) is covered (subject to Limitations and Administrative Guidelines) for the treatment of OSA when all of the following criteria are met: 1. Criteria for CPAP device (II.A.1-3) are met; and 2. CPAP device has been tried and proven ineffective or not tolerated based on a therapeutic trial conducted in either a facility or home setting. Ineffective is defined as documented failure to meet therapeutic goals using a CPAP device during the titration portion of a facility-based study or during home use despite optimal therapy, i.e., proper mask selection and fitting and appropriate pressure settings. C. The use of CPAP or RAD beyond the first three months of therapy is covered (subject to Limitations and Administrative Guidelines) when the following criteria are met: 1. Face-to-face clinical reevaluation by the treating physician has been performed between the 31 st and 91 st day of use and improvement in symptoms has been documented in the medical record (note: a supplier-generated form is not sufficient); and 2. Direct download of data from the device has been performed and adherence has been documented in the medical record by physician and/or kept on file by supplier. Compliance data should be collected on a monthly basis during the initial three months of PAP therapy, until adequate adherence to PAP therapy is established. If the member s adherence is less than 70% during any 30-day period, the supplier and treating physician are expected to address the issues limiting adherence, with the intention of achieving adherence of greater than 70% by the end of the third month. Adherence to therapy is defined as use of PAP

Positive Airway Pressure Devices for the Treatment of Obstructive Sleep Apnea 3 device greater than or equal to four hours per night on 70% of nights during a consecutive thirty day period anytime during the first three months of initial usage; or 3. Direct download of data from the device has been performed and adherence during the third month of usage has been documented in the medical record by the physician and/or kept on file by the supplier. Adherence is defined as use of PAP device greater than or equal to four hours per night on 70% of nights during a thirty day consecutive period during the third month of usage. D. Patients who do not qualify for continuation of PAP device beyond the first three months of therapy are eligible for a one month trial extension for a PAP device, but must have a face-toface clinical reevaluation by the treating clinician. The evaluation should include the following: 1. Determination of the etiology of the failure to respond or adhere to PAP therapy; 2. Patient education regarding the proper use of the equipment and benefits of PAP therapy; and 3. A prompt and intensive effort to improve PAP use (e.g., re-fitting of mask). E. Custom-fitted or custom-fabricated oral appliances, including tongue retaining or mandibular advancing/positioning devices, are covered (subject to Limitations and Administrative Guidelines) for the treatment of OSA when the following criteria are met: 1. Criteria for PAP device are met (II.A-B); 2. Patient has mild to moderate OSA (i.e., AHI greater than or equal to five and less than or equal to 30) and PAP device has been offered and patient declines treatment or PAP device has been tried and could not be tolerated; or 3. Patient has severe OSA (i.e., AHI greater than 30) and RAD (bi-level PAP device) has been tried and could not be tolerated; 4. The device is prescribed by the treating physician following review of the sleep test. 5. The device is provided and billed for by a licensed dentist (DDS or DMD); F. Accessories used with a PAP device are covered when coverage criteria for the PAP device are met. G. A non-heated or heated humidifier is covered when ordered by the treating physician for use with a covered PAP device. III. Limitations A. A PAP device is covered only as a capped rental item. B. Accessories and humidifiers used with a PAP device are not covered when coverage criteria for the PAP device are not met. C. If there is discontinuation of usage of a PAP device at any time, the supplier is expected to ascertain this and stop billing for the equipment and related accessories and supplies. D. A RAD with back-up rate (E0471) is for a primary diagnosis of OSA, unless the prescribed inspiratory pressure exceeds the capability of RADs without back-up (generally an inspiratory pressure greater than 25 cm H 2 O). E. If a PAP device reaches its five-year life expectancy but is in good working order and meets the patient s medical needs, a replacement device will not be covered. F. The use of home oxygen therapy as the sole treatment of OSA (i.e., in the absence of positive airway pressure) is not covered as it is not the most appropriate level of service.

Positive Airway Pressure Devices for the Treatment of Obstructive Sleep Apnea 4 G. An oral interface used with respiratory suction pump (HCPCS code A7047) is not covered as it is not known to be effective in improving health outcomes. IV. Administrative Guidelines A. Precertification is required for initial and continued use of RAD (Bi-level PAP). 1. For initial use, the following documentation from the medical record must be submitted: a. Face-to-face clinical evaluation by the treating physician prior to the sleep test to assess the patient for a sleep related breathing disorder; b. Polysomnogram results supporting diagnosis of OSA; and c. Results from the therapeutic portion of the study showing the PAP titration results; and d. Documentation supporting that a CPAP device has been tried and proven ineffective or not tolerated based on a therapeutic trial conducted in either a facility or home setting. If the trial was conducted in a home setting, a face-to-face clinical evaluation by the treating physician documenting ineffectiveness of or intolerance to CPAP device must be submitted. 2. For continued use, documentation supporting adherence to therapy must be submitted. B. Precertification is required for oral appliances. The following documentation from the medical record must be submitted with all requests for oral appliances: 1. Polysomnogram results supporting diagnosis of OSA; 2. Product name, manufacturer/distributor and model of device; and 3. For mild to moderate OSA, documentation supporting that a PAP device has been offered and declined by the patient or a PAP device has been tried and not tolerated; or 4. For severe OSA, documentation supporting that a RAD device has been tried and not tolerated. C. Precertification is not required for HMO and PPO members for initial and continued use of CPAP for the treatment of OSA when all criteria are met. Documentation supporting medical necessity should be legible, maintained in the patient's medical record, and made available to HMSA upon request. HMSA reserves the right to perform retrospective review using the above criteria to validate if services rendered met payment determination criteria. D. Precertification is required for QUEST Integration members for initial and continued use of PAP. See criteria II.A.1.a-b and II.A.2 above for documentation that must be submitted. E. Polysomnogram and home/portable studies should be performed in accordance with HMSA Polysomnography-Sleep Studies policy criteria. F. This policy only applies to the use of RAD for the treatment of OSA. For other diagnoses (including central and complex sleep apnea), refer to Medicare LCD for Respiratory Assist Devices. G. In general, Medicare criteria for repairs and replacement apply (see Noridian/Medicare DME Supplier Manual Chapter 5) Durable Medical Equipment, Prosthetics, Orthotics, and Supplies. The following documentation must be submitted with all repair and replacement requests: 1. Date that the previous PAP device was provided; 2. Name of manufacturer, model number and serial number; 3. If the device is over five years old, documentation from the supplier s technician stating the problem with the device and that the device cannot be repaired; or

Positive Airway Pressure Devices for the Treatment of Obstructive Sleep Apnea 5 4. If the device is less than five years old, documentation from the manufacturer stating one of the following: a. The device has been evaluated and cannot be repaired; or b. The device is discontinued/obsolete and is no longer being repaired or parts are no longer available. H. A repeat sleep study is not necessary for replacement of a PAP device. Medical record documentation must support that the patient continues to use PAP device. I. HCPCS code E0601 should be used for a CPAP device with C-flex and autotitration features. J. CPT code 94660 (CPAP initiation and management) and HCPCS code A9279 (monitoring feature/device, stand-alone or integrated, any type) are not separately payable to suppliers as the reimbursement for these items is included in the reimbursement for the PAP device. K. PAP device suppliers must provide each patient and/or their caregiver with instruction in the proper use and care of the patient s PAP device and accessories. L. All suppliers must maintain records on each patient s PAP device compliance and must cease billing for all devices and related accessories and supplies as soon as a patient discontinues use of the PAP device. M. Suppliers must contact the patient before dispensing any refills to the original order and may not automatically ship refills on a predetermined basis, even if authorized by the patient or treating physician. Suppliers must confirm that the refilled item continues to be necessary, existing supplies are approaching exhaustion, and the order is up to date. Suppliers must not deliver refills without a valid, documented refill request. Proof of delivery documentation must be maintained for every item. Codes that require precertification: HCPCS codes E0470 E0471 E0601 E0485 E0486 Description Respiratory assist device, bi-level pressure capability, without backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device) Respiratory assist device, bi-level pressure capability, with backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device) Continuous positive airway pressure (CPAP) device Oral device/appliance used to reduce upper airway collapsibility, adjustable or non adjustable, prefabricated, includes fitting and adjustment Oral device/appliance used to reduce upper airway collapsibility, adjustable or non adjustable, custom fabricated, includes fitting and adjustment Codes that do not require precertification, but are related to this service: A4604 Tubing with integrated heating element for use with positive airway pressure device

Positive Airway Pressure Devices for the Treatment of Obstructive Sleep Apnea 6 A7027 A7028 A7029 A7030 A7031 A7032 A7033 A7034 A7035 A7036 A7037 A7038 A7039 A7044 A7045 A7046 E0561 E0562 Combination oral/nasal mask, used with continuous positive airway pressure device, each Oral cushion for combination oral/nasal mask, replacement only, each Nasal pillows for combination oral/nasal mask, replacement only, pair Full face mask used with positive airway pressure device, each Face mask interface, replacement for full face mask, each Cushion for use on nasal mask interface, replacement only, each Pillow for use on nasal cannula type interface, replacement only, pair Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap Headgear used with positive airway pressure device Chinstrap used with positive airway pressure device Tubing used with positive airway pressure device Filter, disposable, used with positive airway pressure device Filter, non-disposable, used with positive airway pressure device Oral interface used with positive airway pressure device, each Exhalation port with or without swivel used with accessories for positive airway devices, replacement only Water chamber for humidifier, used with positive airway pressure device, replacement, each Humidifier, non-heated, used with positive airway pressure device Humidifier, heated, used with positive airway pressure device VI. Important Reminder The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not

Positive Airway Pressure Devices for the Treatment of Obstructive Sleep Apnea 7 be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. VII. References 1. Blue Cross Blue Shield Medical Policy Reference Manual. Diagnosis and medical management of obstructive sleep apnea syndrome. # 2.01.18. November 2014. 2. Centers for Medicare and Medicaid Services. NCD for continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) (240.4). Implementation date 08/04/2008. 3. Centers for Medicare & Medicaid Services. LCD for respiratory assist devices (L11493). Revision effective date 12/01/2014. 4. Kushida CA, Morgenthaler TI, Littner MR, et al. American Academy of Sleep Medicine. Practice parameters for the treatment of snoring and obstructive sleep apnea with Oral appliances. Sleep. 2006 Feb 1; 29(2):240-3. 5. Morgenthaler TI, Aurora RN, Brown T, et al. Standards of Practice Committee of the AASM; American Academy of Sleep Medicine. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: An update for 2007 - Evidence tables. Sleep. 2008 Jan 1; 31(1):141-7. 6. Centers for Medicare & Medicaid Services. LCD for oral appliances for obstructive sleep apnea (L28606). Revision effective date 10/31/2014. 7. Giles TL, Lasserson TJ, Smith BJ et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; (3):CD001106. 8. Lim J, Lasserson TJ, Fleetham J, Wright J. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev 2006; (1):CD004435.

Positive Airway Pressure Devices for the Treatment of Obstructive Sleep Apnea 8 Appendix Definitions A. Apnea is defined as the cessation of airflow for at least 10 seconds. B. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds associated with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% decrease in oxygen saturation. C. Respiratory event related arousal (RERA) is defined as a series of respiratory cycles of increasing/decreasing effort or flattening, recorded by nasal manometry and leading to an arousal that cannot be defined as apnea or hypopnea, with a duration greater than or equal to 10 seconds. D. The apnea-hypopnea index (AHI) is defined as the average number of episodes of apnea and hypopnea per hour of sleep without the use of a positive airway pressure device. The respiratory disturbance index (RDI) is defined as the average number of episodes of apneas, hypopneas, and respiratory event related arousals per hour of sleep without the use of a positive airway pressure device. Note: If the AHI or RDI is calculated based on less than 2 hours of sleep, the total number of recorded events used to calculate the AHI or RDI must be at least the number of events that would have been required in a 2 hours period (i.e., must reach greater than or equal to 10 events).